Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Aclarubicin × Other hematologic neoplasm × Clear all

Phase

Status

Sponsor Class

OTHER 6 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Azacitidine 143 venetoclax 135 Cytarabine 111 Rituximab 84 fludarabine 71 Cyclophosphamide 67 Imatinib Mesylate 56 nilotinib 51 ibrutinib 49 obinutuzumab 43 Dasatinib 42 Decitabine 37 Bendamustine Hydrochloride 37 Daunorubicin 34 acalabrutinib 29 idelalisib 28 Chlorambucil 28 Dexamethasone 24 gilteritinib 23 Idarubicin 23 ofatumumab 19 bosutinib 19 Lenalidomide 19 fludarabine phosphate 18 blinatumomab 18 asciminib 18 ublituximab 16 Vincristine 16 Mitoxantrone 16 zanubrutinib 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04716114 2021-11-02

ALIVE

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡